Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravitreal Aflibercept in Neovascular Age-related Macular Degeneration (nAMD): an Observational Study Assessing Patient Relevant Outcomes, Real-world Treatment Pattern and Effectiveness

NCT03714308 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT03714308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03714308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravitreal Aflibercept in Neovascular Age-related Macular Degeneration (nAMD): an Observational Study Assessing Patient Relevant Outcomes, Real-world Treatment Pattern and Effectiveness
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
January 28, 2019
Completion date
May 12, 2023
Enrollment
554 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration